Halozyme Therapeutics (HALO)
107.94
+0.74 (0.69%)
Upcoming Events
Latest Headlines
Form 4 HALOZYME THERAPEUTICS, For: Sep 09 Filed by: Torley Helen
September 11, 2026 8:35 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
September 3, 2026 6:58 AM - StreetInsider
Form 3 HALOZYME THERAPEUTICS, For: Aug 14 Filed by: Appelhans Dannielle
August 21, 2026 4:55 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Aug 17 Filed by: Torley Helen
August 19, 2026 8:01 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: Aug 14
August 18, 2026 4:04 PM - SEC Filing
Halozyme adds biotech executive Appelhans to its board
August 18, 2026 4:01 PM - StreetInsider
Halozyme Appoints Dannielle Appelhans to its Board of Directors
August 18, 2026 4:01 PM - PR NewsWire
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
August 18, 2026 6:38 AM - StreetInsider
Form 144 HALOZYME THERAPEUTICS, Filed by: Torley Helen
August 17, 2026 5:16 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: Caudill Cortney
August 11, 2026 5:58 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Aug 10 Filed by: Connaughton Bernadette
August 11, 2026 5:44 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: Connaughton Bernadette
August 10, 2026 4:34 PM - SEC Filing
Halozyme Therapeutics (HALO) PT Raised to $105 at TD Cowen
August 7, 2026 8:52 AM - StreetInsider
Halozyme Therapeutics (HALO) PT Raised to $95 at Wells Fargo
August 7, 2026 8:19 AM - StreetInsider
Halozyme Therapeutics (HALO) PT Raised to $93 at Citizens on Royalty Revenue Growth
August 7, 2026 7:32 AM - StreetInsider
Leerink Upgrades Halozyme Therapeutics (HALO) to Outperform
August 7, 2026 7:02 AM - StreetInsider
Halozyme Therapeutics (HALO) Tops Q2 EPS by 47c; raises guidance
August 6, 2026 4:30 PM - StreetInsider
Form 10-Q HALOZYME THERAPEUTICS, For: Jun 30
August 6, 2026 4:16 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: Aug 06
August 6, 2026 4:12 PM - SEC Filing
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
August 6, 2026 4:01 PM - PR NewsWire
Halozyme to Report Second Quarter 2026 Financial and Operating Results
July 23, 2026 8:30 AM - PR NewsWire
Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on 'Solid Partnership Momentum'
July 21, 2026 9:23 AM - StreetInsider
Halozyme and Incyte sign drug delivery licensing agreement
July 20, 2026 8:00 AM - StreetInsider
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
July 20, 2026 8:00 AM - PR NewsWire
Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)
July 14, 2026 4:00 PM - BizWire
Form 4 HALOZYME THERAPEUTICS, For: Jul 08 Filed by: Torley Helen
July 9, 2026 5:20 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Jun 30 Filed by: RAMSAY DAVID A
July 2, 2026 4:46 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Jul 01 Filed by: Snellgrove Darren
July 2, 2026 4:44 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Jul 01 Filed by: Connaughton Bernadette
July 2, 2026 4:42 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: Jun 30
July 2, 2026 4:10 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Jun 29 Filed by: Krishnan Mahesh
June 30, 2026 5:25 PM - SEC Filing
Halozyme names David Ramsay as president of drug delivery
June 30, 2026 4:02 PM - StreetInsider
Halozyme Appoints David Ramsay as President Drug Delivery
June 30, 2026 4:02 PM - PR NewsWire
Form 144 HALOZYME THERAPEUTICS, Filed by: Krishnan Mahesh
June 29, 2026 4:41 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
June 16, 2026 6:43 AM - StreetInsider
Full Article List
